MARKET

KLDO

KLDO

Kaleido Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.95
+0.35
+4.60%
Opening 12:16 07/02 EDT
OPEN
7.70
PREV CLOSE
7.60
HIGH
7.95
LOW
7.56
VOLUME
56.01K
TURNOVER
--
52 WEEK HIGH
11.42
52 WEEK LOW
2.820
MARKET CAP
279.93M
P/E (TTM)
-2.7815
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KLDO stock price target is 13.25 with a high estimate of 19.00 and a low estimate of 8.00.

EPS

KLDO News

More
Kaleido Biosciences Announces CEO Leadership Transition
GlobeNewswire · 06/16 21:45
Kaleido Biosciences announces CEO leadership transition
Seeking Alpha - Article · 06/16 20:58
Kaleido Biosciences Reports Pres, CEO Alison Lawton To Step Down; Chair Mike Bonney To Lead Pres, CEO Office
Benzinga · 06/16 20:47
Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
GlobeNewswire · 06/08 13:30
Theodose Melas-Kyriazi Is The Independent Director of Kaleido Biosciences, Inc. (NASDAQ:KLDO) And Just Spent US$250k On Shares
Simply Wall St. · 06/07 13:54
Kaleido Biosciences to Present During the Goldman Sachs 41st Annual Global Healthcare Conference
GlobeNewswire · 06/04 13:30
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Kaleido Biosciences Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.61% to 25630.00 while the NASDAQ rose 0.11% to 9562.43. The S&P also rose, gaining 0.39% to 3067.67.
Benzinga · 06/02 18:30
MGI, WWR, NNA and ADRO among midday movers
Seeking Alpha - Article · 06/02 16:46

Industry

Biotechnology & Medical Research
+0.89%
Pharmaceuticals & Medical Research
+0.62%

Hot Stocks

Symbol
Price
%Change

About KLDO

Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Its proprietary product platform includes ex vivo screening of microbiome samples from healthy volunteers, ex vivo testing of patient microbiome samples and advancement of its MMT candidates into non- Investigational New Drug Application (IND) human clinical studies. Its ex vivo screening process combines advances in drug discovery with microbiome science.
More

Webull offers kinds of Kaleido Biosciences Inc stock information, including NASDAQ:KLDO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLDO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KLDO stock methods without spending real money on the virtual paper trading platform.